Advertisement

Topics

Latest "Biomarker discovery Driving technologies" News Stories

17:54 EDT 29th June 2016 | BioPortfolio

Here are the most relevant search results for "Biomarker discovery Driving technologies" found in our extensive news archives from over 250 global news sources.

More Information about Biomarker discovery Driving technologies on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Biomarker discovery Driving technologies for you to read. Along with our medical data and news we also list Biomarker discovery Driving technologies Clinical Trials, which are updated daily. BioPortfolio also has a large database of Biomarker discovery Driving technologies Companies for you to search.

Showing "Biomarker discovery Driving technologies" News Articles 1–25 of 11,000+

Relevant

University of Manchester and SCIEX open £18m Biomarker Discovery Centre

The Manchester, UK-based Stoller Biomarker Discovery Centre is a major step forward in precision medicine and making 'industrial' proteomics a reality


Oxford BioDynamics expands biomarker discovery programme for ALS

Oxford BioDynamics is expanding its biomarker discovery programme for the development of companion diagnostic tests for Amyotrophic Lateral Sclerosis (ALS), using its EpiSwitch technology

Biomarker Discovery Offers New Hope for TB Vaccine

A team of scientists led by Oxford University have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis. The researchers have identified new biomarkers for Tuberculosis (TB) which have shown for the first time why immunity from the widely used Bacillus Calmette-Guérin (BCG) vaccine is so variable. The biomarkers will also provide valuable clues ...


Biomarker drug discovery company Blueprint Bio receives $7.5mm in Series A round

Blueprint Bio Inc. (personalized medicine using biomarker drug discovery) secured $7.5mm in its Series A financing round from Forentis Partners LLC. The company will use the proceeds to further develop its intellectual property and support additional drug discoveries.

Biomarkers of Cancer

Biomarkers of Cancer Larry H. Bernstein, MD, FCAP, Curator LPBI   Biomarker Discovery Gets a Fix on Cancer GEN Feb 1, 2016 (Vol. 36, No. 3)   http://www.genengnews.com/gen-articles/biomarker-discovery-gets-a-fix-on-cancer/5674/ Just Because Cancer Is a Moving Target—Emerging Here, Eluding Treatment There—Doesn’t Mean It Can’t Be Tracked Kathy Liszewsky http://www.genengnews.com/Med...

Epistem announces collaboration with Sanofi Aventis

Epistem plc, the UK biotechnology and personalised medicine company today announced a collaboration with sanofi-aventis U.S. Inc. relating to the use of Epistem's proprietary biomarker gene expression profiling and immunohistochemistry technologies. Under the terms of the agreement sanofi-aventis has entered into a 3 year collaboration with Epistem to provide discovery through to clinical biomarke...

Stemina Biomarker Discovery Announces Rebranding of Its Diagnostics Business, New Board Member Kevin Krenitsky, MD, and Progress from Its Clinical Study

Tuesday, May 10th 2016 at 1:32pm UTC MADISON, Wis.–(BUSINESS WIRE)– Stemina Biomarker Discovery Inc. today announced it has rebranded its diagnostics business to more accurately represent its focus on neurological disorders. NeuroPointDX is transforming diagnosis and allowing more precise treatment of neurological disorders based on the patient’s metabolism. The company’s proprieta...

Biomarker drug discovery company Blueprint Bio receives $7.5mm in early-stage funding

Blueprint Bio Inc. (personalized medicine using biomarker drug discovery) secured $7.5mm in early-stage funding from Forentis Partners LLC. The company will use the proceeds to further develop its intellectual property and support additional drug discoveries.

Biomarker discovery offers hope for new TB vaccine

A team of scientists led by Oxford University have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis.

Smarter driving, using your phone

Mobile-based telematics — apps and hardware that measure driving behaviors — may be the future of safer roads. Increasingly, people are using these technologies to improve their own driving habits, while insurance companies use the data to offer rewards and discounts to safe drivers. One of the most prominent companies — and one of the […]

Denovo Biomarkers: Robert Little. Providing a novel biomarker solution to personalize drug development

Robert Little, the Chief Business Officer of Denovo Biomarkers reveals to Fintan Walton the use of its industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples.

Horizons of drug discovery

Horizons of drug discovery Larry H. Bernstein, MD., FCAP, Curator LPBI   Phenotypic and Biomarker-based Drug Discovery NY Acad Sci.    http://www.nyas.org/Publications/Ebriefings/Detail.aspx Organizers: Michael Foley (Tri-Institutional Therapeutics Discovery Institute), Ralph Garippa (Memorial Sloan-Kettering Cancer Center), David Mark (F. Hoffmann-La Roche), Lorenz Mayr (Astra Zeneca), Joh...

Ten New Grants Support Alzheimer's Drug Discovery & Biomarker Development

MIQE compliance in expression profiling and clinical biomarker discovery

Metabolomics in rheumatic diseases: desperately seeking biomarkers

In the setting of inflammatory diseases, metabolic profiling has potential applications in diagnosis, monitoring and defining disease pathogenesis. This Review focuses on metabolomic studies in rheumatic diseases, including discussion of state-of-the-art technologies, recent insights into disease mechanisms and treatment targets, and the feasibility of metabolomics for biomarker discovery.

Technology, not capacity, driving Catalent’s biologics strategy

Differentiated technologies buoyed by the recent $600m conjugation deal with Roche is driving Catalent’s biologics business, the firm told Biopharma-Reporter at BIO.

BluePen Biomarkers announces collaboration with the University of Pennsylvania

(University of Pennsylvania) The University of Pennsylvania has co-founded and structured BluePen Biomarkers in collaboration with BluePrint Bio, Inc. and Emerald Logic, Inc. to conduct biomarker research and identification. BluePen is creating a comprehensive biomarker measurement and discovery pipeline for the acceleration of personalized medicine.

Research discovers neuroprotective protein in blood is biomarker of Alzheimer's disease

(American Friends of Tel Aviv University) A new discovery by Tel Aviv University researchers takes the medical community a leap forward in the process of effectively screening and diagnosing Alzheimer's disease. The study proposes a new biomarker for cognitive aging and Alzheimer's disease, the levels of which can be easily monitored in routine blood tests.

Interactive Motion Technologies Names CEO and Chairman of the Board

WATERTOWN, MA -- Interactive Motion Technologies Inc. announced Nov. 25 the appointment of Jules M. Fried as CEO and Hermano Igo Krebs, PhD, as chairman of the board of directors, effective immediately. Fried joined Interactive Motion Technologies in a consulting capacity in May 2015. "I am delighted joining Interactive Motion Technologies at this exciting time, when rehabilitation provide...

Quest Diagnostics spins Enterix's biomarker business off into newco Clinical Genomics

Following its acquisition of colorectal cancer testing company Enterix Inc. earlier this year, Quest Diagnostics Inc. has spun off that company's biomarker business into a new firm, Clinical Genomics Technologies Pty. Ltd. Quest holds a 19.9% equity stake in the spin-off, according to regulatory filings.

Biomarker Market for Diagnostic Applications is Expected to Reach $30.6 Billion Globally by 2020

Portland, OR, June 19, 2016 --(PR.com)-- According to a new report titled "Biomarkers Market (Diagnostic Applications in Risk Assessment, Molecular Diagnostics, Disease Diagnosis, Drug Discovery & Development, Drug Formulation, Forensic Applications and Others) - Global Industry Analysis, Emerging Technologies, Competitive Intelligence, Growth Trends, Size, Share, Opportunities and Forec...

Crawford Technologies' New Voiceye Solution Featured on Discovery Channel's NewsWatch Program

Toronto, ON (PRWEB) March 17, 2016 Crawford Technologies announced today that its new Voiceye solution – allowing visually-impaired customers to read printed pages - has been featured on the Discovery’s Channel’s NewsWatch program. NewsWatch is a 30-minute segment airing weekly in more than 2...

CardiNor Signs CV Biomarker Deal With Bioventix

Early-stage Norwegian cardiovascular biomarker developer CardiNor has signed a deal with UK-based sheep monoclonal antibody company Bioventix, which will supply antibodies for use in CardiNor’s project to develop a biomarker to better target patients that should be implanted with Implantable Cardioverter Defibrillators.

Alan Wright, CMO of Roche Diagnostics, to Keynote at Biomarkers Summit 2016

San Diego, CA, February 18, 2016 --(PR.com)-- Alan Wright, Chief Medical Officer of Roche Diagnostics, will give a keynote presentation on “Creating Personalized Diagnostics Ecosystems” at GTCbio’s Biomarkers Summit 2016 to be held on March 21-23, 2016 in San Diego, CA. With a heavy national focus on the bottom line of healthcare, the “what” and “how” of...

Enabling Taste-Masking & Delivery With New Technologies

Enabling Taste-Masking & Delivery With New Technologies What You'll Learn: • The new technologies designed to optimize taste-masking and delivery • The science behind specific multiparticulate formulation technologies • Case studies on the development and use of specific multiparticulate formulation technologies HOST Stephanie Guzowski Editor Drug Discovery & Development GUESTS Ed...


Quick Search
Advertisement
 

News Quicklinks